EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal

Francesco Samarelli iD, Giovanni Graziano iD, Nicola Gambacorta iD, Elisabetta Anna Graps, Francesco Leonetti iD, Orazio Nicolotti iD, Cosimo Damiano Altomare iD

Viruses · 2024

DOI: 10.3390/v16030450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Francesco Samarelli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy. Hauptthemen laut MEDLINE: Post-Acute COVID-19 Syndrome, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People affected by COVID-19 are exposed to, among others, abnormal clotting and endothelial dysfunction, which may result in deep vein thrombosis, cerebrovascular disorders, and ischemic and non-ischemic heart diseases, to mention a few. Treatments for COVID-19 include antiplatelet (e.g., aspirin, clopidogrel) and anticoagulant agents, but their impact on morbidity and mortality has not been proven. In addition, due to viremia-associated interconnected prothrombotic and proinflammatory events, anti-inflammatory drugs have also been investigated for their ability to mitigate against immune dysregulation due to the cytokine storm. By retrieving patent literature published in the last two years, small molecules patented for long-COVID-related blood clotting and hematological complications are herein examined, along with supporting evidence from preclinical and clinical studies. An overview of the main features and therapeutic potentials of small molecules is provided for the thromboxane receptor antagonist ramatroban, the pan-caspase inhibitor emricasan, and the sodium–hydrogen antiporter 1 (NHE-1) inhibitor rimeporide, as well as natural polyphenolic compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Post-Acute COVID-19 SyndromeCOVID-19HumansAspirinAnticoagulantsBlood Coagulation

Stichwörter der Autor:innen

caspase inhibitorslong COVIDprocyanidinsramatrobanvascular issues

Substanzen

AspirinAnticoagulants

Autor:innen und Institutionen

  • Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.
  • ARESS Puglia-Agenzia Regionale Strategica per la Salute ed il Sociale, I-70121 Bari, Italy.

ORCID-Profile: Francesco Samarelli, Giovanni Graziano, Nicola Gambacorta, Francesco Leonetti, Orazio Nicolotti, Cosimo Damiano Altomare

Zitieren

APA

Samarelli, F., Graziano, G., Gambacorta, N., Graps, E. A., Leonetti, F., Nicolotti, O., & Altomare, C. D. (2024). Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal. Viruses. https://doi.org/10.3390/v16030450

Vancouver

Samarelli F, Graziano G, Gambacorta N, Graps EA, Leonetti F, Nicolotti O, et al. Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal. Viruses. 2024. doi:10.3390/v16030450

BibTeX
@article{Samarelli2024,
  author = {Samarelli, Francesco and Graziano, Giovanni and Gambacorta, Nicola and Graps, Elisabetta Anna and Leonetti, Francesco and Nicolotti, Orazio and Altomare, Cosimo Damiano},
  title = {Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16030450}
}
Kostenlos starten →